Trials / Sponsors / Convalife (Shanghai) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Industry · 8 registered clinical trials — 6 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplu Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | CVL006 Combination Therapy in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2025-09-10 |
| Not Yet Recruiting | Clinical Study of CVL006 Injection in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-11-20 |
| Not Yet Recruiting | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations Advanced Solid Tumor | Phase 2 | 2024-08-10 |
| Not Yet Recruiting | Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Eso Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis | Phase 2 | 2024-04-30 |
| Unknown | CVL237 Tablets for APDS/PASLI PI3K and P110delta Hyperactivation Syndrome | Phase 2 / Phase 3 | 2024-03-30 |
| Not Yet Recruiting | CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency Advanced Solid Tumors | Phase 2 | 2023-12-20 |
| Unknown | Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations NSCLC | Phase 2 | 2023-11-20 |